Cerus(US:CERS)2026-01-12 13:06Revenue Performance - Preliminary full-year 2025 product revenue totaled $206.1 million, representing a 14% increase over 2024 results[4] - Preliminary fourth quarter 2025 product revenue was $57.8 million, reflecting a 14% increase compared to the fourth quarter of 2024[4] - INTERCEPT Fibrinogen Complex (IFC) contributed $16.7 million to full-year 2025 revenue, marking an 80% year-over-year increase[4] - The company expects full-year 2026 product revenue to be between $224 million and $228 million, indicating a year-over-year growth of 9%-11%[4] - Expected full-year 2026 IFC revenue is projected to be $20 million to $22 million, representing a growth of approximately 20% to 30% from 2025[4] Product Development and Regulatory Updates - The PMA application submission to the FDA for INT200 is anticipated in mid-2026[4] - Results from the Phase 3 RedeS study of the INTERCEPT Blood System for Red Blood Cells are expected in the second half of 2026[4] Operational Highlights - Approximately 3 million INTERCEPT treated blood component doses were produced for patients in about 40 countries during 2025[3] - Cerus aims to expand its commercial reach and advance its product development pipeline in 2026[3] Financial Reporting - The company plans to provide complete financial results for Q4 and full-year 2025 in early March 2026[5]